Preventing Pandemics By Dr Nathaniel Hentz Over the years, influenza has taken the lives of millions. While vaccines are helping to reduce the damage caused by the virus, there is still a major capacity shortfall. Could access to US and European expertise and quality training improve capacity and prevent the… Read More
Induced pluripotent stem cells in high-throughput cellular screening By Dr Carolyn E. Peluso With the failure rates of drug candidates continuing to present phenomenal costs to the pharmaceutical industry, this article discusses how newly emerging induced pluripotent stem cell (iPSC) technologies have the potential to be an effective tool in… Read More
Nanobioscience & Nanotechnology: The Future Of Personalised Medicine By Abhishek Gottipati, Joseph M. Sanders and Dr Scott A. Tenenbaum Nanotechnology has been more than a buzz word in the business world for a long time now and has been striding ahead, living up to the hype. There is a general… Read More
Metabolomics: Analytic Methods Driving Exponential Understanding By Dr Ian D. Jardine Metabolomics is distinct from genomics and proteomics in several significant respects. Where genes and proteins are unique to specific organisms, metabolites are ubiquitous throughout the plant and animal kingdoms. Compared with proteomics and genomics, which quantify the building blocks… Read More
Targeting Tau For Alzheimer’s Disease and Related Neurodegenerative Disorders By Dr Eliot J. Davidowitz and Dr James G. Moe There is no effective treatment for Alzheimer’s disease (AD) even though the prevalence of this neurodegenerative disorder and its associated costs are growing along with an ageing population. This article discusses… Read More
Biological Expression Language (BEL): Ringing In A Common Language For The Life Sciences By Ted Slater and Dr Diane H. Song Established fields of study preserve their history and support advancement by developing and using a common language, without which those fields could not progress at a reasonable pace. The… Read More
Meeting the challenge of healthcare-associated infections with new antimicrobials: with a focus on Clostridium difficile By Professor Peter Hawkey and Dr Katie Hardy Healthcare-associated infections (HCAI), previously known as hospital acquired infections (HAI), are defined as infections resulting from medical care or treatment in hospital. HCAI may be caused by… Read More
Epigenetics: Are We Hitting The Mark? By Dr Andrew J. Pope and Dr Amy M. Quinn During the last few years, advances in the understanding of epigenetic processes have led to an explosion in interest in this area as a potential source of new targets for the discovery of medicines. Read More
Enzyme-linked Immunosorbent Assays (ELISA): Recent Innovations Take Analyte Detection To New Levels By Dr John Comley Enzyme-linked immunosorbent assays (ELISA) have been around as one of the primary methods of analyte detection for more than four decades. Over the years many changes to the basic format have resulted in assay… Read More
The Challenges Of The Changing Drug Discovery Model By Dr Mark Downs and Dr Tom Blackburn The drug development industry is restructuring worldwide. This brings different ways of working and new challenges. As the industry moves away from internally focused research to an external model, project management and communication of… Read More
Editing the Human Genome: Role in Functional Genomics and Translational Medicine By Dr Chris Torrance and Eric Rhodes It is now readily accepted that we are in a post genomic era. With the steady flow of genomic information available to researchers worldwide, the focus turns to ways to analyse this… Read More
New Tools Increase Accessibility to High Content Screening Assays By Dr John Comley There have been major improvements in the instrument offerings and tools that enable high content screening (HCS) over the past decade. In this review we examine the status of high content screening assays today; the motivation to… Read More
Ubiquitination, E3 Ligases and Drug Discovery - Novel technologies for a challenging pathway By Dr Neil Wilkie and Dr Steve Davies Does ubiquitin drug discovery provide the opportunity for a new class of therapeutic agents? This article argues that new technological advances are removing many of the barriers that have… Read More
Stem Cells: Cell-Based Assays and the World of Small Molecules By Dr Christina N. Ramirez, Dr Dana C. Duré and Dr Hakim Djaballah Stem cells remain a hot topic in academia and industry alike, and with the potential to cause a paradigm shift where many believe in their ability to… Read More
Innovate While Derisking Drug Development: Yes We Can! Taher Abbasi, Pradeep Fernandes, Dr Shireen Vali and Professor Gurkirpal Singh The outlook for the drug industry continues to remain bleak in context of productivity and success rates. In spite of ongoing increase in R&D expenses and technology revolutions in the genomics… Read More
In Vivo Imaging In Drug Development: Gamma Scintigraphy By Dr Alyson Connor Gamma scintigraphy is a non-invasive technique with applications in the development of drug products and the assessment of pharmacodynamic effects in humans. It enables the assessment of critical performance parameters that in vitro techniques attempt, but often fail,… Read More